Kirin Holdings aims to expand the number of "premedi" outlets to 300*1 by the end of 2024, six times the current number, and to 2,000 by 2027, in order to solve social issues for more dispensing pharmacies and patients.

New businesses created through the Kirin Business Challenge
This service is a new business born out of the Kirin Business Challenge, Kirin's in-house business solicitation system that aims to create innovation in business domains ranging from food to medicine. Through the development of this business, we aim to solve the problems of dispensing pharmacies and patients, especially small and medium-sized ones, and to grow our business in the health science field.
1 Number of stores as of October 31, 2023: 50 stores
What is "premedi"?
Background of Service Development
In dispensing pharmacies, infrequently handled drugs are sometimes out of stock and cannot be provided according to the prescription or take time to arrange and are not given to patients until the next day or later. Our survey revealed that 44% patients across Japan have experienced not receiving the drug they prescribed, and 35% of them have changed their pharmacy because their impression of the pharmacy worsened. 2
On the other hand, according to a survey by the Ministry of Health, Labour and Welfare, more than 200,000 yen*3 per store per year is disposed of as surplus inventory at dispensing pharmacies due to expiration or other reasons. 4
For small- and medium-sized dispensing pharmacies in particular, it is a difficult management issue to balance stocking an excess or shortage of infrequently handled pharmaceuticals and minimizing waste.
Service Features
premedi" is a prescription drug service for dispensing pharmacies that uses AI to predict the probability of drug use at each pharmacy and can order approximately 100 different types of drugs in small lots of 10 to 30 tablets. The service is characterized by its ability to appropriately manage the inventory of pharmaceuticals that are handled infrequently at each dispensing pharmacy, and "premedi" purchases pharmaceuticals that are approaching their expiration date and replaces them with new ones.
With the introduction of this service, dispensing pharmacies will be able to deliver even infrequently handled drugs to patients as prescribed, thereby reducing excess inventory. In addition, by reducing the time and effort required by pharmacies to secure pharmaceuticals, pharmacists will have more time to perform their primary duties, such as providing medication guidance.
2 Kirin survey, October 2022 web-based questionnaire Target: Men and women in their 30-70s (N=10,000)
3 Monthly average of the amount of discarded pharmaceuticals to insurance pharmacies by the Ministry of Health, Labor and Welfare: 19,230 yen in 2017 and 21,808 yen in 2018.
4 Questionnaire survey on the current status and reduction of immovable inventory drugs in insurance pharmacies (cited from J-STAGE, 2019)
https://www.jstage.jst.go.jp/article/yakkyoku/11/2/11_nt.2019-1905/_pdf/-char/ja
Future Development
The test rollout of "premedi" began on Tuesday, April 26, 2022, mainly in the Tokyo metropolitan area. We have received several comments from dispensing pharmacies that "missing products were prevented," "patients were not kept waiting," and "employees (pharmacists) are able to use their time for their primary duties," confirming the need for "premedi," so we began nationwide deployment at the end of 2022.
In November 2023, Takata Pharmaceutical, a generic drug developer with added value in terms of ease-of-use and ease-of-take, will be invited as a collaborative partner to further expand this service, and Takata Pharmaceutical will begin a trial to support "premedi" sales.
Through the expansion of "premedi", Kirin will further promote the CSV*6 management that the Kirin Group has set forth by creating a state where even small and medium-sized dispensing pharmacies can immediately receive a variety of medicines, thereby solving issues faced by dispensing pharmacies and patients, promoting "family pharmacists and pharmacies" as stated in the "Vision of Pharmacies for Patients "*5 of the Ministry of Health, Labour and Welfare, and realizing economic value. " and economic value, and further promote the Kirin Group's CSV*6 management.
5 Ministry of Health, Labour and Welfare, "Vision of Pharmacies for Patients" (Friday, October 23, 2015)https://www.mhlw.go.jp/file/04-Houdouhappyou-11121000-Iyakushokuhinkyoku-Soumuka/vision_1.pdf
6 Abbreviation for Creating Shared Value. Creating value that can be shared with customers and society.
The Kirin Group will contribute to the realization of a spiritually rich society by expanding new joys in "food and health" through manufacturing that focuses on nature and people.
Reference: Press release on "PREMEDI" (Tuesday, April 26, 2022)https://www.kirinholdings.com/jp/newsroom/release/2022/0426_01.html
Business Overview of "premedi
1. service name "premedihttps://premedi.kirin.co.jp/
2. Provided by Kirin Holdings Company, Limited
3. Service Description: AI-based prescription medicine service that responds to urgent prescriptions for pharmaceuticals
The AI will select a list of drugs that each dispensing pharmacy does not have in stock and that are likely to be needed by patients. The list is used to make a final decision*1 on the drugs to be purchased at the dispensing pharmacy. 1. Selection from a list of ethical drugs that is determined on a case-by-case basis.
Storage shelves for selected pharmaceuticals are available for rent. Pharmaceuticals can be purchased in small lots from our pharmaceutical distribution partners.
Used portions can be easily ordered online and replenished.
Pharmaceuticals that are approaching their expiration date can be purchased by the sales partner*2, so that a sufficient supply of expired pharmaceuticals is always available. Dispensing pharmacies can simultaneously reduce inventory risk and shortage risk of infrequently handled drugs.
2 Purchase by pharmaceutical sales partners is limited to pharmaceuticals that meet the conditions specified separately.

About Takata Pharmaceuticals
Takada Pharmaceutical Co., Ltd. is a research-based company that is primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products, with the management philosophy of "contributing to human health through the development of original products and the appropriate supply of high-quality products," including value-added generic drugs with strength in the pediatric field. The company is mainly engaged in research and development, manufacturing, and sales of pharmaceutical products as an R&D-oriented company.
| name of company | Takata Pharmaceutical Co. |
| Establishment | November 1928 |
| Location | 1-11-1 Numakage, Minami-ku, Saitama City, Saitama Prefecture |
| representative | Hiroki Takada, President and Representative Director |
| Business Overview | Manufacture and sales of pharmaceuticals, soft drinks and health foods |
| uniform resouce locator | https://www.takata-seiyaku.co.jp/ |









